Clinical Trials in Illinois

Showing 15621-15640 of 19,692 trials

BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia

NCT01669174

This study will assess the pharmacodynamics, pharmacokinetics, safety and tolerability of BYM338 in patients with COPD and cachexia. The primary outcome will be a change in thigh muscle volume compared to placebo. The study will last for approximately 24 weeks.

Chronic Obstructive Pulmonary Disease (COPD) With Cachexia

Novartis Pharmaceuticals67 participantsStarted Sep 2012

Torrance, California, United States • Savannah, Georgia, United States • Normal, Illinois, United States +6 more locations

COMPLETEDPhase 394 miles

Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy

NCT01076764

Primary Objective: * To demonstrate the superior efficacy (composite of all-cause death + Myocardial Infarction (MI)) of Otamixaban to Unfractionated Heparin (UFH) + Eptifibatide Secondary Objectives: * To demonstrate the superior efficacy (composite of all-cause death + MI + any stroke) of Otamixaban as compared to UFH + Eptifibatide * To document the effect of Otamixaban on rehospitalization or prolongation of hospitalization due to a new episode of myocardial ischemia/myocardial infarction as compared to UFH + eptifibatide * To document the effect on mortality (all cause death) of Otamixaban as compared to UFH + eptifibatide * To document the safety of Otamixaban as compared to UFH + eptifibatide * To document the effect of Otamixaban on thrombotic procedural complications during the index Percutaneous Coronary Intervention (PCI) as compared to UFH + eptifibatide

Acute Coronary Syndrome

Sanofi13,220 participantsStarted Apr 2010

Huntsville, Alabama, United States • Phoenix, Arizona, United States • Phoenix, Arizona, United States +604 more locations

BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia

Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy

Find Trials by Condition in Illinois

NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction

A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer

LDE225 for Patients With PTCH1 or SMO Mutated Tumors

Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis

Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)

Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment

A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)

Tocilizumab for Chronic Graft-versus-Host Disease Treatment

Feeding Tolerance Evaluation

Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC

Developing a COPD Case Finding Methodology for Primary Care

Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population

Strattice in Repair of Inguinal Hernias

Study of Electrical Impedance Myography (EIM) in ALS

The Esteem® Hearing Implant Post Approval Study

Efficacy and Safety of XRP0038/NV1FGF in Critical Limb Ischemia Patients With Skin Lesions